Germany-Based Generic Pharma Company Nidda BondCo GmbH Preliminary 'B+' Rating Affirmed; Outlook Stable - S&P Global Ratings’ Credit Research

Germany-Based Generic Pharma Company Nidda BondCo GmbH Preliminary 'B+' Rating Affirmed; Outlook Stable

Germany-Based Generic Pharma Company Nidda BondCo GmbH Preliminary 'B+' Rating Affirmed; Outlook Stable - S&P Global Ratings’ Credit Research
Germany-Based Generic Pharma Company Nidda BondCo GmbH Preliminary 'B+' Rating Affirmed; Outlook Stable
Published Nov 24, 2017
5 pages (2133 words) — Published Nov 24, 2017
Price US$ 150.00  |  Buy this Report Now

About This Report

  
Abstract:

Regulatory agreement for the financial sponsors' full acquisition of Nidda is still pending. We are affirming all of our preliminary ratings on Nidda BondCo, including our 'B+' long-term corporate credit rating and our 'B-' rating on the unsecured debt. The stable outlook reflects our view that Nidda will remain resilient and continue to display solid operating performance and generate sufficient earnings to support its expansion. PARIS (S&P Global Ratings) Nov. 24, 2017--S&P Global Ratings said today that it had affirmed its preliminary 'B+' long-term corporate credit rating on Nidda BondCo GmbH (Nidda), the parent of the group's holding company, Nidda Healthcare Holding AG (Nidda Healthcare). The outlook is stable. At the same time, we affirmed the preliminary 'B+' issue rating

  
Brief Excerpt:

...+ Regulatory agreement for the financial sponsors' full acquisition of Nidda is still pending. + We are affirming all of our preliminary ratings on Nidda BondCo, including our 'B+' long-term corporate credit rating and our 'B-' rating on the unsecured debt. + The stable outlook reflects our view that Nidda will remain resilient and continue to display solid operating performance and generate sufficient earnings to support its expansion. PARIS (S&P Global Ratings) Nov. 24, 2017--S&P Global Ratings said today that it had affirmed its preliminary 'B+' long-term corporate credit rating on Nidda BondCo GmbH (Nidda), the parent of the group's holding company, Nidda Healthcare Holding AG (Nidda Healthcare). The outlook is stable. At the same time, we affirmed the preliminary 'B+' issue rating on the secured debt, including the 1.7 billion term loan B, the 735 million senior secured notes, and the 400 million revolving credit facility. The recovery rating on these instruments is '4', reflecting...

  
Report Type:

Ratings Action

Ticker
1509417D@GR
Issuer
Sector
Global Issuers
Country
Region
Europe, Middle East, Africa
Format:
PDF Adobe Acrobat
Buy Now

S&P Global Ratings’ Credit Research—S&P Global Ratings’ credit research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P Global Ratings also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.

About the Author


Cite this Report

  
MLA:
S&P Global Ratings’ Credit Research. "Germany-Based Generic Pharma Company Nidda BondCo GmbH Preliminary 'B+' Rating Affirmed; Outlook Stable" Nov 24, 2017. Alacra Store. May 15, 2025. <http://www.alacrastore.com/s-and-p-credit-research/Germany-Based-Generic-Pharma-Company-Nidda-BondCo-GmbH-Preliminary-B-Rating-Affirmed-Outlook-Stable-1955247>
  
APA:
S&P Global Ratings’ Credit Research. (). Germany-Based Generic Pharma Company Nidda BondCo GmbH Preliminary 'B+' Rating Affirmed; Outlook Stable Nov 24, 2017. New York, NY: Alacra Store. Retrieved May 15, 2025 from <http://www.alacrastore.com/s-and-p-credit-research/Germany-Based-Generic-Pharma-Company-Nidda-BondCo-GmbH-Preliminary-B-Rating-Affirmed-Outlook-Stable-1955247>
  
US$ 150.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.